Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ONDANSETRON HYDROCHLORIDE DIHYDRATE
GlaxoSmithKline (Ireland) Limited
ONDANSETRON HYDROCHLORIDE DIHYDRATE
4 MG/5ml
Oral Solution
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
GLAXOSMITHKLINE (LOGO) PACKAGE LEAFLET: INFORMATION FOR THE USER ZOFRAN® 4 MG/5 ML SYRUP ONDANSETRON READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions about your illness or your medicine, ask your doctor, nurse or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1 What Zofran syrup is and what it is used for 2 What you need to know before you take Zofran syrup 3 How to take Zofran syrup 4 Possible side effects 5 How to store Zofran syrup 6 Contents of the pack and other information 1 WHAT ZOFRAN SYRUP IS AND WHAT IT IS USED FOR Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics. Zofran syrup is used for: preventing nausea and vomiting caused by chemotherapy [http://www.netdoctor.co.uk/medicines/effect/cancer.shtml]or radiotherapy for cancer [http://www.netdoctor.co.uk/cancer/index.shtml] preventing nausea and vomiting after surgery Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses. Zofran syrup should start to work within one or two hours of taking a dose. You must talk to a doctor if you do not feel better or i Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zofran 4 mg/5 ml Syrup. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5ml contains 4mg ondansetron (as ondansetron hydrochloride dihydrate). Each 5ml also contains 2.1g of Sorbitol (E420) and 3mg of ethanol. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral solution. Clear, colourless to light yellow liquid with characteristic strawberry odour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zofran Syrup is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran Syrup is also indicated for the prevention of post-operative nausea and vomiting. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zofran is also available for parenteral and rectal use to allow the route of administration and dosing to be flexible. CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING (CINV AND RINV): The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge. _CINV AND RINV IN ADULTS:_ The recommended oral dose is 8mg 1-2 hours before treatment, followed by 8mg orally 12 hours later. _Highly emetogenic chemotherapy:_ For patients receiving highly emetogenic chemotherapy a single oral dose of up to 24 mg ondansetron taken together with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used. After the first 24 hours, oral treatment with Zofran should be continued for up to 5 days and rectal treatment for up to 3 days after a course of treatment. The recommended oral dose is 8mg to be taken twice daily. PAEDIATRIC POPULATION _CINV IN CHILDREN Read the complete document